Physician profile
Ahmad Nawid Latifi
NPI 1063933240
$1,470.31
in general payments reported to CMS, 2019-2025
21 companies · $595 in 2025
The $595 reported for 2025 was more than what a typical Nuclear Cardiology provider received nationally (typical 2025 total: $434).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $15.14 · 2021: $35.20 · 2022: $84.30 · 2023: $344 · 2024: $396 · 2025: $595.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,085 · Education: $250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,085.42 |
| Education | $250.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $347.79 | 2023-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Ensite, Gallant |
| Boston Scientific Corporation | $272.25 | 2023-2025 | Watchman, Watchman Flx, Zoom Wireless Transmitter |
| Amgen INC. | $123.05 | 2024-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals Lp | $93.85 | 2022-2025 | Farxiga |
| Medtronic, INC. | $84.97 | 2024-2025 | Cobalt Dr Mri Surescan, Linq II |
| Inspire Medical Systems, INC. | $63.53 | 2025 | Inspire |
| E.R. Squibb & Sons, L.L.C. | $62.13 | 2022-2025 | Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.01 | 2020-2024 | Jardiance |
| Cvrx, INC. | $51.19 | 2025 | Barostim Neo System |
| Kestra Medical Technology Services, INC. | $47.01 | 2025 | Assure Wcd |
| Pfizer INC. | $39.70 | 2022-2024 | |
| Scpharmaceuticals INC. | $37.97 | 2025 | |
| Zap Surgical Systems, INC. | $35.20 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $30.07 | 2024 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $28.82 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $19.12 | 2024 | Kengreal |
| Merck Sharp & Dohme LLC | $17.83 | 2023 | Verquvo, Bridion |
| Novo Nordisk INC | $15.48 | 2025 | Wegovy |
| Bridgebio Pharma, INC. | $15.13 | 2025 | Attruby |
| Abiomed | $14.38 | 2022 | |
| Kiniksa Pharmaceuticals, Ltd. | $12.83 | 2023 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahmad Nawid Latifi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.